Clinical Trials
Phase 2 Tests D-Serine
A recruiting Phase 2 trial is testing D-serine against placebo in 100 people with Parkinson's, looking at whether it can change disease severity scores over time. This is not evidence of benefit yet; it is a controlled study of a brain-signaling approach that showed enough earlier safety and rationale to justify a larger test.
Clinical trialLevel: Under evaluationStudy in peopleWhat the study tells us: This is not evidence of benefit yet; it is a controlled study of a brain-signaling approach that showed enough earlier safety and rationale to justify a larger test.
Limit: An ongoing trial does not prove effectiveness or mean the treatment is available.
Source: clinicaltrials.govIntranasal Combo Trial Still Recruiting
The NOSE-PD Phase 2 study is recruiting 56 participants to compare intranasal insulin plus glutathione with matched placebo as an add-on therapy. The goal is to evaluate safety, tolerability, and early efficacy, so families should view it as an investigational approach rather than a proven treatment.
Clinical trialLevel: Under evaluationStudy in peopleWhat the study tells us: The goal is to evaluate safety, tolerability, and early efficacy, so families should view it as an investigational approach rather than a proven treatment.
Limit: An ongoing trial does not prove effectiveness or mean the treatment is available.
Source: clinicaltrials.govGene Therapy Follow-Up Opens Soon
A new long-term follow-up study will track six people with severe Parkinson's who previously received the IPS101A gene therapy product in an earlier Phase 1 trial. The study is designed to watch for long-term safety and durability signals, which is the kind of follow-up needed before any gene-therapy program can mature.
Clinical trialLevel: Under evaluationStudy in peopleWhat the study tells us: The study is designed to watch for long-term safety and durability signals, which is the kind of follow-up needed before any gene-therapy program can mature.
Limit: An ongoing trial does not prove effectiveness or mean the treatment is available.
Source: clinicaltrials.gov
Breakthrough Treatments
DBS Cohort Shows Long-Term Benefits
A nationwide hospital-database study followed 79,845 adults hospitalized with Parkinson's, including 482 who had deep brain stimulation. After statistical balancing, DBS was linked with lower risks of facility placement and mortality over several years, but this was an observational study and cannot prove DBS caused those outcomes.
Observational studyLevel: Association, not causationObserves people or recordsWhat the study tells us: After statistical balancing, DBS was linked with lower risks of facility placement and mortality over several years, but this was an observational study and cannot prove DBS caused those outcomes.
Limit: Without randomization, an association may reflect other differences rather than the intervention causing the result.
Source: pubmed.ncbi.nlm.nih.govDBS Neurofeedback Shows Early Signal
Researchers tested short-term neurofeedback using implanted DBS electrodes in eight people with Parkinson's. Participants were able to change beta brain rhythms across multiple sessions, suggesting a possible future add-on strategy for movement control, though the study was small and exploratory.
Research studyLevel: Not stated in reportDesign not statedWhat the study tells us: Participants were able to change beta brain rhythms across multiple sessions, suggesting a possible future add-on strategy for movement control, though the study was small and exploratory.
Limit: A promising signal is not yet a validated diagnostic test and cannot guide treatment by itself.
Source: pubmed.ncbi.nlm.nih.govSafer Stem-Cell Matrix Advances
A laboratory study identified a defined, xeno-free matrix that supported growth and differentiation of midbrain dopamine-producing cells. This matters because stem-cell therapy development depends on manufacturing cells safely and consistently, but the work remains preclinical and is not a patient-ready therapy.
Preclinical researchLevel: EarlyLaboratory or animal modelWhat the study tells us: This matters because stem-cell therapy development depends on manufacturing cells safely and consistently, but the work remains preclinical and is not a patient-ready therapy.
Limit: Results from cells or animals may not reproduce in people.
Source: pubmed.ncbi.nlm.nih.gov
Lifestyle Interventions
Tai Chi Review Shows Benefits
A systematic review and meta-analysis of 15 randomized trials found that traditional Chinese exercise was associated with better cognition, sleep quality, and quality of life in Parkinson's. The authors noted that longer programs and at least 180 minutes per week may be more helpful, but those subgroup findings need cautious interpretation.
Systematic reviewLevel: Synthesized evidenceCombines multiple studiesWhat the study tells us: A systematic review and meta-analysis of 15 randomized trials found that traditional Chinese exercise was associated with better cognition, sleep quality, and quality of life in Parkinson's.
Limit: The conclusion depends on the quality and differences among the included studies; it cannot predict an individual outcome.
Source: pubmed.ncbi.nlm.nih.govDual-Task Training Improves Balance
A randomized study of 36 participants tested 12 weeks of dual-task training with or without melatonin. Both training groups improved motor capacity, freezing of gait, and quality of life versus placebo, while the melatonin-plus-training group showed extra gains in one-leg balance and leg strength.
Clinical trialLevel: Under evaluationStudy in peopleWhat the study tells us: Both training groups improved motor capacity, freezing of gait, and quality of life versus placebo, while the melatonin-plus-training group showed extra gains in one-leg balance and leg strength.
Limit: An ongoing trial does not prove effectiveness or mean the treatment is available.
Source: pubmed.ncbi.nlm.nih.govExercise Pathway Looks Biologically Plausible
A mouse-model study found that 10 weeks of treadmill running improved movement and reduced Parkinson-like pathology while activating an irisin-PINK1/Parkin pathway in microglia. This gives a possible biological explanation for exercise benefits, but it is animal research and should not be treated as proof of the same effect in people.
Preclinical researchLevel: EarlyLaboratory or animal modelWhat the study tells us: This gives a possible biological explanation for exercise benefits, but it is animal research and should not be treated as proof of the same effect in people.
Limit: Results from cells or animals may not reproduce in people.
Source: pubmed.ncbi.nlm.nih.gov
Emerging Research
MAPT Genetics Broadens Beyond Europe
A GP2 and LARGE-PD genetics study analyzed MAPT-region haplotypes in 20,507 people with Parkinson's and 11,841 controls across eleven ancestry groups. The results support MAPT H1 involvement in Parkinson's risk and highlight why genetic studies need broader ancestry representation.
Research studyLevel: Not stated in reportDesign not statedWhat the study tells us: The results support MAPT H1 involvement in Parkinson's risk and highlight why genetic studies need broader ancestry representation.
Limit: A genetic association does not determine an individual’s future and does not mean a targeted therapy is available.
Source: pubmed.ncbi.nlm.nih.govUrine Panel Suggests Biomarker Candidates
A pilot study compared urine metabolites from 15 people with Parkinson's and their matched healthy spouses, using machine-learning consensus to prioritize candidates. The proposed five-metabolite panel is exploratory, not a diagnostic test, but it gives researchers specific targets to validate in larger cohorts.
Observational studyLevel: Association, not causationObserves people or recordsWhat the study tells us: The proposed five-metabolite panel is exploratory, not a diagnostic test, but it gives researchers specific targets to validate in larger cohorts.
Limit: Without randomization, an association may reflect other differences rather than the intervention causing the result.
Source: pubmed.ncbi.nlm.nih.govXNA Sensor Speeds MicroRNA Testing
Researchers developed XENO-Q, a three-step Xeno Nucleic Acid sensor platform for measuring circulating microRNAs linked to Parkinson's diagnostics. In a demonstration study, it identified a two-marker signature that distinguished Parkinson's from other neurodegenerative conditions, but clinical usefulness still requires independent validation. Generated daily from public research databases. For informational purposes only — not medical advice.
Research studyLevel: Not stated in reportDesign not statedWhat the study tells us: Researchers developed XENO-Q, a three-step Xeno Nucleic Acid sensor platform for measuring circulating microRNAs linked to Parkinson's diagnostics.
Limit: Without randomization, an association may reflect other differences rather than the intervention causing the result.
Source: pubmed.ncbi.nlm.nih.gov
This report is for informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.